A Deep Dive into the Ocean: Evaluation of Marine Compounds Bioactivity in the Omics Era

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 3413

Special Issue Editors


E-Mail
Guest Editor
Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy
Interests: functional proteomics; global proteomics; drug-target deconvolution; mass spectrometry; biochemistry; metabolomics; metabolites quantification

E-Mail Website
Guest Editor
Department of Pharmacy, University of Naples 'Federico II', Via Tommaso De Amicis 95, 80131 Naples, Italy
Interests: proteomics; functional proteomics; metabolomics; analytical chemistry; small-molecules/proteins interactions; marine-inspired compounds
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, SA, Italy
Interests: skin wound healing; angiogenesis; endothelial to mesenchymal and epithelial to mesenchymal transition; cancer biology; cell transfection; in vitro cultures; wound healing in mice; cell migration and invasion; pharmacology in general; extracellular vesicles isolation, characterization and use
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Comprising approximately half of the world's biodiversity, the marine environment represents a massive source of structurally multifaceted compounds, showing a range of complex and biologically relevant chemotypes. Indeed, marine products have been, and still are, a valuable source of drug discovery, being endowed with a wide spectrum of bioactivity. Despite the recent advances, a plethora of marine bioactive compounds still need to be explored to elucidate their mechanism of action. In this scenario, omics sciences represent a robust toolbox of complementary approaches, which clarify several aspects of bioactive molecule behavior, from its ability to influence certain cell transcriptomes, proteomes and/or metabolomes regarding their ability to specifically bind a set of proteins and thus exert their biological functions.

This Special Issue aims to showcase original research or review papers exploring marine bioactive compounds using omics strategies coupled with molecular biology and/or pharmacological approaches to obtain an in-depth characterization of their mechanisms of action.

Dr. Elva Morretta
Dr. Maria Chiara Monti
Dr. Raffaella Belvedere
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • functional proteomics
  • proteins expression profiling
  • proteins post-translational modifications analysis
  • metabolomics
  • transcriptomics
  • multi-omics approaches
  • biological activity
  • pharmacological profiling.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2081 KiB  
Article
Identification of Mortalin as the Main Interactor of Mycalin A, a Poly-Brominated C-15 Acetogenin Sponge Metabolite, by MS-Based Proteomics
by Elva Morretta, Alessandra Capuano, Gilda D’Urso, Antonia Voli, Matteo Mozzicafreddo, Sonia Di Gaetano, Domenica Capasso, Marina Sala, Maria Carmina Scala, Pietro Campiglia, Vincenzo Piccialli and Agostino Casapullo
Mar. Drugs 2024, 22(2), 52; https://doi.org/10.3390/md22020052 - 23 Jan 2024
Viewed by 1323
Abstract
Mycalin A (MA) is a polybrominated C-15 acetogenin isolated from the marine sponge Mycale rotalis. Since this substance displays a strong antiproliferative bioactivity towards some tumour cells, we have now directed our studies towards the elucidation of the MA interactome through functional [...] Read more.
Mycalin A (MA) is a polybrominated C-15 acetogenin isolated from the marine sponge Mycale rotalis. Since this substance displays a strong antiproliferative bioactivity towards some tumour cells, we have now directed our studies towards the elucidation of the MA interactome through functional proteomic approaches, (DARTS and t-LIP-MS). DARTS experiments were performed on Hela cell lysates with the purpose of identifying MA main target protein(s); t-LiP-MS was then applied for an in-depth investigation of the MA–target protein interaction. Both these techniques exploit limited proteolysis coupled with MS analysis. To corroborate LiP data, molecular docking studies were performed on the complexes. Finally, biological and SPR analysis were conducted to explore the effect of the binding. Mortalin (GRP75) was identified as the MA’s main interactor. This protein belongs to the Hsp70 family and has garnered significant attention due to its involvement in certain forms of cancer. Specifically, its overexpression in cancer cells appears to hinder the pro-apoptotic function of p53, one of its client proteins, because it becomes sequestered in the cytoplasm. Our research, therefore, has been focused on the possibility that MA might prevent this sequestration, promoting the re-localization of p53 to the nucleus and facilitating the apoptosis of tumor cells. Full article
Show Figures

Graphical abstract

15 pages, 4855 KiB  
Article
Taxonomic, Phylogenomic and Bioactivity Profiling of Novel Phycosphere Bacterium from Model Cyanobacterium Synechococcus elongatus PCC 7942
by Xiaoling Zhang, Jiaquan Xu, Jun Dai, Lei Zhang, Lijuan Feng, Xiaoqing Tian and Qiao Yang
Mar. Drugs 2024, 22(1), 36; https://doi.org/10.3390/md22010036 - 07 Jan 2024
Viewed by 1746
Abstract
Phycosphere niches host rich microbial consortia that harbor dynamic algae–bacteria interactions with fundamental significance in varied natural ecosystems. Hence, culturing the uncultured microbial majority of the phycosphere microbiota is vital for deep understanding of the intricate mechanisms governing the dynamic interactions, and also [...] Read more.
Phycosphere niches host rich microbial consortia that harbor dynamic algae–bacteria interactions with fundamental significance in varied natural ecosystems. Hence, culturing the uncultured microbial majority of the phycosphere microbiota is vital for deep understanding of the intricate mechanisms governing the dynamic interactions, and also to provide novel and rich microbial resources, and to discover new natural bioactive metabolites. Synechococcus elongatus PCC 7942 is a robust model cyanobacterium widely used in environment, synthesis biology, and biotechnology research. To expand the number of novel phycosphere species that were brought into culture and to discover the natural bioactivities, we presented a new yellow-pigmented bacterium named ABI-127-1, which was recovered from the phycosphere of PCC 7942, using an optimized bacterial isolation procedure. Combined polyphasic taxonomic and phylogenomic characterization was performed to confidently identify the new isolate as a potential novel species belonging to the genus Qipengyuania. The observed bioactivity of strain ABI-127-1 with promoting potential towards the growth and CO2 fixation efficiency of the host microalgae was measured. Additionally, the bacterial production of active bioflocculant exopolysaccharides was evaluated after culture optimization. Thus, these findings revealed the potential environmental and biotechnological implications of this new microalgae growth-promoting bacterium isolated from the phycosphere microenvironment. Full article
Show Figures

Graphical abstract

Back to TopTop